Plasmodium Falciparum Clinical Trials

9 recruitingLast updated: May 11, 2026

There are 9 actively recruiting plasmodium falciparum clinical trials across 12 countries. Studies span Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Nanoro, Burkina Faso, Kisumu, Kenya, Ahero, Kisumu County, Kenya. Updated daily from ClinicalTrials.gov.


Plasmodium Falciparum Trials at a Glance

9 actively recruiting trials for plasmodium falciparum are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Nanoro, Kisumu, and Ahero. Lead sponsors running plasmodium falciparum studies include University of Oxford, Novartis Pharmaceuticals, and London School of Hygiene and Tropical Medicine.

Browse plasmodium falciparum trials by phase

About Plasmodium Falciparum Clinical Trials

Looking for clinical trials for Plasmodium Falciparum? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Plasmodium Falciparum trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Plasmodium Falciparum clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

Malaria (Plasmodium Falciparum)
Victoria Biomedical Research Institute1,116 enrolled1 locationNCT07559370
Recruiting
Phase 3

Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar

Malaria,FalciparumMalaria, VivaxPlasmodium Vivax+1 more
London School of Hygiene and Tropical Medicine19,200 enrolled2 locationsNCT06923592
Recruiting
Phase 2

Dose Finding Trial of R21/Matrix-M in School Children

Malaria (Plasmodium Falciparum)
University of Oxford40 enrolled1 locationNCT07074665
Recruiting
Phase 4

Mass Vaccine and Drug Administration, Bangladesh

Plasmodium falciparum malaria
University of Oxford10,000 enrolled2 locationsNCT06068530
Recruiting
Phase 3

A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines

Uncomplicated Plasmodium falciparum malaria
University of Oxford1,680 enrolled1 locationNCT05951595
Recruiting
Phase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

Uncomplicated Plasmodium falciparum malaria
Novartis Pharmaceuticals327 enrolled12 locationsNCT05750628
Recruiting
Phase 4

Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in Binh Phuoc, Gia Lai and Phu Yen provinces, Viet Nam in 2021.

Patients infected Plasmodium vivaxPatients infected Plasmodium falciparum
World Health Organization42 enrolled3 locationsACTRN12621001743853
Recruiting
Phase 1

Safety, Tolerability, Pharmacokinetics (including Food Effect) of Single Ascending Doses of SAR441121 in healthy male subjects.

Parasitic Diseases - Plasmodium falciparum infection
sanofi-aventis australia ptd ltd62 enrolled1 locationACTRN12618001783213
Recruiting
Phase 1

A Phase I, pharmacokinetic trial, in healthy Asian and Caucasian volunteers for investigating the pharmacokinetic profiles of Eurartesim (trademark) (40 mg Dihydroartemisinin/320 mg Piperaquine Phosphate)

Anti-Malarial Treatment of uncomplicated plasmodium falciparum malaria
CPR Pharma Services Pty Ltd20 enrolled1 locationACTRN12610000178044